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Abstract
Experience with debridement and prosthesis retention in early prosthetic joint infections (PJI) due to Staphylococcus aureus is
scarce. The present study aimed to evaluate the outcome and predictors of failure. Patients prospectively registered with an early
PJI due to S. aureus and 2 years of follow-up were reviewed. Demographics, co-morbidity, type of implant, clinical manifestations,
surgical treatment, antimicrobial therapy and outcome were recorded. Remission was deﬁned when the patient had no symptoms
of infection, the prosthesis was retained and C-reactive protein (CRP) was £1 mg/dL. Univariate and multivariate analysis were per-
formed. Fifty-three patients with a mean ± SD age of 70 ± 10.8 years were reviewed. Thirty-ﬁve infections were on knee prosthe-
sis and 18 were on hip prosthesis. The mean ± SD duration of intravenous and oral antibiotics was 10.6 ± 6.7 and 88 ± 45.9 days,
respectively. After 2 years of follow-up, 40 (75.5%) patients were in remission. Variables independently associated with failure were
the need for a second debridement (OR 20.4, 95% CI 2.3–166.6, p 0.006) and a CRP > 22 mg/dL (OR 9.8, 95% CI 1.5–62.5,
p 0.01). The onset of the infection within the 25 days after joint arthroplasty was at the limit of signiﬁcance (OR 8.3, 95% CI 0.8–
85.6, p 0.07). Debridement followed by a short period of antibiotics is a reasonable treatment option in early PJI due to S. aureus.
Predictors of failure were the need for a second debridement to control the infection a CRP > 22 mg/dL and the infection onset
within the ﬁrst 25 days after joint arthroplasty.
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Introduction
Debridement and prosthesis retention in early post-surgical
prosthetic joint infections (PJI) is an accepted therapeutic
approach when the duration of symptoms is <2–4 weeks and
there are no radiological signs of loosening [1,2]. In the last
15 years, the combination of rifampin with other antibiotics
(i.e. ﬂuoroquinolones) has demonstrated a higher success
rate [3–8]; however, the number of patients included in
these studies with a PJI due to S. aureus was low.
The main predictor of failure when S. aureus PJI is treated
mainly with b-lactams is the duration of symptoms before
debridement [9]. Prosthesis that were debrided >2 days
after onset of symptoms were associated with a higher prob-
ability of treatment failure. There are no speciﬁc studies
directed to identify predictors of failure among patients with
S. aureus PJI treated mainly with a combination of oral anti-
staphylococcal antibiotics.
The present study aimed to evaluate: (i) the efﬁcacy of
debridement, retention of the implant, a short course of
intravenous antibiotics and an oral antibiotic regimen com-
bining two anti-staphylococcal agents and (ii) predictors of
failure among a prospectively followed-up cohort of acute
and early PJI due to S. aureus.
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Patients and Methods
From January 2000 to October 2007, all patients with a PJI
(hip hemiarthroplasty, total hip and knee arthroplasty) were
prospectively registered in a database and prospectively
followed up. Relevant information about demographics,
co-morbidity, type of implant (hip or knee prosthesis), clini-
cal manifestations, leukocyte count and value of C-reactive
protein (CRP) at the moment of admission for infection,
surgical treatment, isolated microorganism, antimicrobial
therapy and outcome were recorded. For the present study,
only those cases with an early PJI due to S. aureus with at
least 2 years of follow-up were included and retrospectively
reviewed.
Early PJI due to S. aureus in the present study was
deﬁned by the presence of local inﬂammation of acute
onset (<15 days of symptoms duration) during the
ﬁrst 2 months after joint arthroplasty, macroscopic
evidence of extension of the infection through the capsule
during debridement and isolation of S. aureus in deep
samples.
In terms of debridement, pre-existing incisions were
always used, necrotic tissue was excised and the joint was
washed with 6–9 L of sterile water. The components were
left in situ after conﬁrming that no signs of loosening were
found at the time of surgery. In knee arthroplasties, the poly-
ethylene component was removed and replaced with a new
component and, in total hip arthroplasties, modular compo-
nents were substituted. When systemic or local signs of
infection persisted after debridement, the patient was taken
back to the operating room for repeating the irrigation and
debridement. The need for a second debridement, within
the ﬁrst 10 days after the ﬁrst one, was not considered as
failure. Three or more deep samples of synovial ﬂuid and
periprosthetic tissue were submitted to the microbiology
laboratory. In addition, blood cultures were performed to
patients with fever at the moment of admission for infection.
An antibiogram for all the isolates was performed by micro-
dilution method.
After debridement, a broad-spectrum intravenous anti-
microbial regimen including vancomycin (1 g/12 h) plus
ceftazidime (2 g/8 h) was started and maintained until deﬁni-
tive microbiological results were obtained. When S. aureus
was susceptible to methicillin, vancomycin was switched to
intravenous cloxacillin (2 g/4 h). The deﬁnitive oral antibiotic
treatment was levoﬂoxacin (500 mg/24 h) plus rifampin
(600 mg/24 h), except in those cases with resistant strains
or polymicrobial infection, in which an alternative was
selected according to the antibiogram. The protocol of our
hospital recommends 10 days of intravenous antibiotics,
although the duration of oral antibiotics was not standard-
ized and it was decided by a member of the team (A.S.) in
each case according to the clinical manifestations and the
CRP value.
After being discharged, patients were followed-up monthly
when they were receiving treatment and every 3–6 months
after ﬁnishing the therapy. Outcome was evaluated according
to: (i) remission, when the patient had no symptoms of infec-
tion, the prosthesis was retained and CRP was £1 mg/dL
after 2 years of follow-up and (ii) failure, when inﬂammatory
signs and high CRP remained during treatment or
re-appeared after completing it (relapse or re-infection
depending on the microorganism isolated) or when the
patient developed an aseptic loosening that required the
exchange of prosthesis, but deep samples taken during
surgery were negative.
Statistical analysis
Variables analyzed were age, sex, co-morbidity (having or
not having one or more of the following entities: diabetes
mellitus, liver cirrhosis, chronic renal failure, rheumatoid
arthritis or chronic obstructive pulmonary disease), type
of prosthesis (hip or knee), age of implant, duration of
symptoms, presence of fever, leukocyte count, CRP value,
positive blood cultures, the need for a second debride-
ment, resistance to methicillin or ﬂuoroquinolones and
polymicrobial infection. For the statistical analysis, continu-
ous variables were explored and categorized as: age
(£70 years or >70 years); time from arthroplasty to diag-
nosis of infection (age of implant) (£25 days or >25 days);
duration of symptoms (£2 days or >2 days); leukocyte
count (£10 000 cells/mm3 or >10 000 cells/mm3); and CRP
(£22 mg/dL or >22 mg/dL), at the moment of admission
for infection. Categorical variables were compared by the
the chi-square test or Fisher’s exact test when necessary
and continuous variables were compared by Student’s
t test. Variables signiﬁcantly associated with failure in the
univariate analysis were included in a forward and back-
wards stepwise logistic regression model to identify the
independent variables associated with failure. For the analy-
sis, the dependent variable (failure) included relapse, rein-
fection and aseptic loosening. The Kaplan–Meier survival
method was used to estimate the cumulative probability of
treatment success of the whole cohort. Statistical signiﬁ-
cance was deﬁned as a two-tailed p <0.05. The analysis
was performed using SPSS, version 12.0 (SPSS, Inc., Chicago,
IL, USA).
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Results
During the study period, 53 patients met the inclusion crite-
ria of the study. The mean ± SD age of the cohort was
70 ± 10.8 years; 25 were male and 28 were female, 35 infec-
tions were on knee prosthesis and 18 were on hip prosthe-
sis, and all except two were primary arthroplasties. The
mean ± SD duration of intravenous and oral antibiotics was
10.6 ± 6.7 and 88 ± 45.9 days, respectively. Patients with
good outcome were followed-up for at least 2 years, except
one case who died after 6 months as a result of unrelated
cause and without evidence of failure. The cumulative proba-
bility of being in remission according to the Kaplan–Meier
survival curve is shown in Fig. 1.
Six patients failed before starting oral antibiotics and
underwent implant removal. The other 47 patients received
an oral combination of two anti-staphylococcal agents. Rifam-
pin (600 mg/24 h) was administered to 43 patients and it
was associated with levoﬂoxacin (500 mg/24 h) in 33 cases,
clindamycin (300 mg/8 h) in four, linezolid (600 mg/12 h) in
three, amoxicillin-clavulanate (875/125 mg/8 h) in two and
cotrimoxazole (800 mg/12 h) in one. Among cases that did
not received rifampin (n = 4), two received levoﬂoxacin plus
cotrimoxazole and two received levoﬂoxacin plus linezolid.
The mean ± SD duration of rifampin combinations was
78 ± 45 days, whereas the mean ± SD duration of combina-
tions without rifampin was 138 ± 51 days (p 0.01). Linezolid
was administered for 90 days in all cases. After a mean ± SD
follow-up of 879.3 ± 205 days, 40 patients (75.5%) were in
remission. Thirteen patients (24.5%) failed as a result of rein-
fection in seven cases (ﬁve during treatment and two after
ﬁnishing antibiotics), relapse in ﬁve (three during treatment
and two after ﬁnishing antibiotics) and aseptic failure in one.
In relapse cases, no resistant strains to rifampin or other
antibiotics were isolated.
The main characteristics of the patients according to their
outcome are summarized in Table 1. Variables signiﬁcantly
associated with failure were onset of infection £25 days
after joint arthroplasty (p 0.01), a C-reactive protein at
admission >22 mg/dL (p 0.01), documented bacteraemia
(p 0.02) and the need for a second debridement (p 0.002).
Failure was more frequent in patients older than 70 years,
with co-morbidity, fever or leukocyte count >10 000 cells/
mm3, and when the infection affected a knee prosthesis or
it was polymicrobial; however, these variables did not
achieve statistical signiﬁcance. In the multivariate analysis,
variables independently associated with failure were the
need for a second debridement (OR 20.4, 95% CI 2.3–
166.6, p 0.006) and a CRP > 22 mg/dL (OR 9.8, 95% CI
1.5–62.5, p 0.01).
Discussion
The success rate in our cohort of patients with a PJI due to
S. aureus treated with debridement and retention of the
implant after at least 2 years of follow-up was 75.5% (40 out
of 53), considering relapse, reinfection and aseptic loosening
as failure, and 90.5% (48 out of 53) when only relapse was
considered as failure. Clinical experience focus on infections
due to this microorganism using a conservative surgical
approach is scarce. Brandt et al. [9] analyzed 33 patients by
administering an intravenous b-lactam for 4–6 weeks and
showed a cumulative probability of failure (2 years after
debridement) of 70%. The results obtained in the present
study and those from other studies [6–8,10] support the
usefulness of rifampin in staphylococcal infections (including
S. aureus and coagulase-negative staphylococci); however, we
cannot rule out the possibility that the differences observed
between Brandt’s study and others could be the result of
factors such as the higher percentage of patients with bactae-
remia (36%) or prosthesis loosening (39%).
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FIG. 1. Kaplan–Meier survival curve for the whole cohort. The x-
axis represents days since debridement and the y-axis represents the
proportion without treatment failure. Vertical bars indicate censored
patients in remission.
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In general, previous experience used 450 mg/12 h of
rifampin, whereas the present study and our own previous
experience [8] suggests that 600 mg/24 h of rifampin is
equally effective. Rifampin is a concentration-dependent anti-
biotic and the best pharmacodynamic parameter related to
its activity is Cmax/MIC [11]. Rifampin administration in a
600 mg monodose is not only easier to administer and well
tolerated (mild nausea in two cases), but also could result in
a higher Cmax/MIC than the 450 mg/12 h dosage. In addition,
rifampin is added for killing bioﬁlms and the doubling time of
bioﬁlm bacteria is signiﬁcantly longer than planktonic [12];
therefore, the administration of rifampin once daily as for
Mycobacterium tuberculosis infections, appears reasonable.
The available literature concerning factors associated with
outcome in PJI treated with debridement is scarce and, to
allow the analysis of larger series, different aetiological
microorganisms and different surgical approaches were
pooled. A common factor associated with failure in the prec-
edent studies is the isolation of S. aureus. Predictors of fail-
ure in our cohort were the need for a second debridement
to control the infection, CRP > 22.5 mg/dL and the onset of
infection within the ﬁrst 25 days after implantation. These
factors suggest a higher bacterial inoculum, infection due to
more pathogenic S. aureus strains or infection in inmunocom-
promised patients that favours the bacterial growth. The last
option is unlikely because age and co-morbidity were not sig-
niﬁcantly different between patients in remission and those
who failed. The main predictor of treatment failure in PJI
due to S. aureus treated with b-lactams is the duration of
symptoms [9]. Interestingly, this variable was not associated
with treatment failure in our cohort. A possible explanation
for this discrepancy could be that b-lactams are less effective
in vitro than rifampin for eradicating bacterial bioﬁlms [13]
and, for b-lactams, it is critical to start therapy as soon as
possible.
The current recommendation for the duration of antibi-
otic treatment in acute PJI treated without removing the
implant is 2–4 weeks of intravenous therapy followed by oral
regimen for 3 months in hip infections and 6 months in knee
infections [2]. However, this recommendation is based on
few observational studies [14]. Recently, Byren et al. [15]
analyzed 112 patients treated with debridement and 6 weeks
TABLE 1. Characteristics of
patients according to outcome
Characteristics Failure (n = 13)a Remission (n = 40) p
Mean ± SD age (years) 67 ± 11.9 71 ± 10.4 0.25
Age > 70 years (%) 4 (30.8) 23 (57.5) 0.11
Sex (female) (%) 6 (46.2) 22 (55) 0.75
Comorbidityb(%) 6 (46.2) 10 (25) 0.17
Primary arthroplasty (%) 13 (100) 38 (95) 1
Type of prosthesis (%)
Hip 2 (15.4) 16 (40)
Knee 11 (84.6) 24 (60) 0.17
Mean ± SD age of prosthesis (days) 16.3 ± 7.2 26 ± 17.9 0.06
Age of prosthesis, days (%)
£25 12 (92.3) 21 (52.5)
>25 1 (7.7) 19 (47.5) 0.01
Mean ± SD duration of symptoms (days) 5.1 ± 4.2 5.7 ± 4.5 0.66
Duration of symptoms (days)
£2 4 (30.8) 14 (35)
>2 9 (69.2) 26 (65) 1
Fever 5 (38.5) 7 (17.5) 0.14
Mean ± SD leukocyte count (cells/mm3) 10149.2 ± 3838.9 8697.1 ± 3097.3 0.17
Leukocyte count > 10 000 cells/mm3 6 (46.2) 9 (24.3) 0.13
Mean ± SD C-reactive protein (mg/dL) 14.5 ± 12.2 7.8 ± 10.5 0.06
C-reactive protein > 22 mg/dL 6 (46.2) 5 (12.8) 0.01
Methicillin-resistant Staphylococcus aureus 0 4 (10) 0.56
Fluoroquinolone-resistant S. aureus 2 (15.4) 6 (12.8) 1
Bacteremia 4 (30.8) 2 (5) 0.02
Polymicrobial infection 6 (46.2) 9 (22.5) 0.15
Need for second debridement 6 (46.2) 2 (5) 0.002
Duration of oral antibioticc
>90 days 3 (49.2) 12 (30)
£90 days 4 (57.1) 28 (70) 0.66
Oral antibioticc
Rifampin 6 (85.7) 37 (92.5) 0.48
Levoﬂoxacin 5 (71.4) 32 (80) 0.63
Clindamycin 1 (14.3) 3 (7.5) 0.48
Cotrimoxazole 1 (14.3) 2 (5) 0.28
Linezolid 0 5 (12.5) 1
Amoxicillin-clavulanate 1 (14.3) 1 (2.5) 0.27
Mean ± SD days of follow-up from debridement 155 ± 114.1 879.3 ± 205.2 –
aIncluding, relapse (n = 5), reinfection (n = 7) and aseptic loosening (n = 1).
bDiabetes mellitus, liver cirrhosis, chronic renal failure, rheumatoid arthritis or chronic obstructive pulmonary dis-
ease.
cRefers to those patients who received oral antibiotics (n = 47). In this group, 40 patients were in remission.
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of intravenous b-lactams or glycopeptides followed by oral
regimen including rifampin for a minimum of 12 months.
Despite the prolonged treatment, in S. aureus infections, the
failure rate was 27.6% (13 out of 47), which was similar to
that in the present study (24.5%) with a mean ± SD duration
of intravenous and oral antibiotics of 10.6 ± 6.7 and
88 ± 45.9 days, respectively. The results of the present study
support those previously presented by Berdal et al. [16] in
29 patients with acute post-surgical infections (18 due to
S. aureus) treated with 3–7 days of intravenous antibiotics
and 3 months of oral rifampin regimen. The rationale for this
protocol is that, in acute foreign-body related infections, two
bacterial populations could be found: free-ﬂoating (plank-
tonic) bacteria that are responsible for acute symptoms and
sessile (bioﬁlm) bacteria that colonize the implant surface
and are responsible for relapse after stopping antibiotic. One
of the main differences between these two bacterial popula-
tions is that sessile bacteria double their population every
30 h, whereas planktonic do so in 1.6 h [12], explaining the
tolerance to cell-wall active antibiotics shown by bioﬁlm bac-
teria [13,17]. Planktonic bacteria could be eradicated through
debridement and effective antibiotics against growing bacteria
(e.g. b-lactams) for no longer than 7–10 days, similar to
other wound infections without foreign material. To eradi-
cate bioﬁlm bacteria, it is necessary to use antibiotics with a
better performance against stationary phase bacteria such as
rifampin [18].
Early PJI frequently were polymicrobial (28.3%) and,
although this might appear to be a high rate, in a recent
article by Moran et al. [19], the rate of polymicrobial infec-
tions in acute PJI was found to be even higher than in the
present study (47%). The high prevalence shown by Moran
et al. [19], together with the high reinfection (seven out of
13 failures; 53.8%) rate observed in the present study,
leads to the hypothesis that co-pathogens were not always
identiﬁed in the microbiology laboratory and that directing
the antibiotic therapy exclusively to S. aureus resulted in
patient failure. In the future, to improve the outcome of
these patients, it would be necessary to improve microbio-
logical techniques aiming to identify all the possible aetio-
logical agents and to standardize a broad-spectrum
antibiotic until deﬁnitive results are obtained. An alterna-
tive explanation for reinfections may be contamination dur-
ing open debridement or wound superinfection during the
post-operative period. Therefore, we recommend a broad-
spectrum prophylaxis during debridement as well as the
need to take care of the wound, including plastic surgery
in those cases where the soft tissue is damaged, or to
avoid skin tension and further necrosis (especially in knee
prosthesis).
A recent retrospective study comparing infections due to
methicillin-susceptible (n = 33) and -resistant (n = 12) S. aur-
eus showed that resistance to methicillin was an independent
factor associated with treatment failure. However, only three
cases with MRSA infection were managed with debridement
and retention of the implant [20]. Five patients with MRSA
infection were included in our series and all of them were in
remission. Three patients received rifampin plus linezolid (for
90 days in two cases and 100 days in one) and two received
rifampin plus clindamycin (for 60 days in both cases). Indeed,
previous studies have documented the efﬁcacy of linezolid in
PJI [21,22].
In conclusion, debridement with retention of the implant
followed by a short period of intravenous antibiotics and
an oral combination of rifampin plus other antistaphylococ-
cal agent is a reasonable treatment option in early PJI due
to S. aureus. Predictors of failure were the need for a sec-
ond debridement to control the infection, a CRP > 22 mg/dL
and infection onset within the ﬁrst 25 days after joint
arthroplasty. In these cases, it is necessary to further
evaluate the efﬁcacy of other surgical strategies and new
antibiotics.
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